Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-13
2007-03-13
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S236800, C514S254020, C514S326000, C514S340000, C514S377000, C544S060000, C544S137000, C544S369000, C546S209000, C546S271400, C548S234000
Reexamination Certificate
active
10530810
ABSTRACT:
Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
REFERENCES:
patent: 6197975 (2001-03-01), Goulet et al.
patent: 6399773 (2002-06-01), Liu et al.
Manley et al. “Therapies directed at vascular endothelial growth factor” Expert Opin. Investig. Drugs, 2002, pp. 1715-1736.
Davies et al. “Structure-based design of cyclin-dependent kinase inhibitors” Pharmacology & Therapeutics, 2002, pp. 125-133.
Toogood, Peter “Cyclin-Dependent Kinase Inhibitors for Treating Cancer” Medicinal Research Reviews, 2001, pp. 487-498.
Brown Matthew Lee
Cheung Mui
Dickerson Scott Howard
Gauthier Cassandra
Harris Philip Anthony
Fox Jennifer L.
Kosack Joseph R.
Lemanowicz John L.
McKane Joseph K.
SmithKline Beecham Corporation
LandOfFree
1,3-Oxazole compounds for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3-Oxazole compounds for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-Oxazole compounds for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3729684